Mar 12, 2024 8:05am EDT Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Mar 05, 2024 4:01pm EST Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Feb 27, 2024 8:05am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
Jan 04, 2024 8:05am EST Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
Dec 08, 2023 8:05am EST Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
Nov 07, 2023 4:01pm EST Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
